What are the first-line antibiotic recommendations for an adult patient with no significant medical history presenting with a sinus or chest bacterial infection?

First-Line Antibiotics for Sinus and Chest Bacterial Infections in Adults

Acute Bacterial Sinusitis

For adults with confirmed acute bacterial sinusitis, amoxicillin-clavulanate 875 mg/125 mg twice daily for 5-10 days is the preferred first-line antibiotic. 1, 2

Confirming Bacterial Sinusitis Before Prescribing

Do not prescribe antibiotics unless the patient meets one of three specific criteria:

• Persistent symptoms ≥10 days without clinical improvement 1, 2, 3
• Severe symptoms (fever ≥39°C with purulent nasal discharge or facial pain) for ≥3 consecutive days 1, 2, 3
• "Double sickening" - worsening symptoms after initial improvement from a viral upper respiratory infection 1, 2, 3

Most acute rhinosinusitis (98-99.5%) is viral and resolves spontaneously within 7-10 days without antibiotics. 1, 3

Dosing Specifications

• Standard dose: Amoxicillin-clavulanate 875 mg/125 mg twice daily for 5-10 days 2, 3
• High-dose regimen: Amoxicillin-clavulanate 2 g/125 mg twice daily for patients with recent antibiotic use (within past month), age >65 years, moderate-to-severe symptoms, comorbid conditions, or immunocompromised state 2, 3

The IDSA recommends amoxicillin-clavulanate over plain amoxicillin based on concern for ampicillin-resistant Haemophilus influenzae and Moraxella catarrhalis, achieving 90-92% predicted clinical efficacy. 1, 2, 4

For Penicillin-Allergic Patients

Non-severe penicillin allergy (rash, mild reactions):

• Second-generation cephalosporins: cefuroxime-axetil 2
• Third-generation cephalosporins: cefpodoxime-proxetil or cefdinir 2
• The risk of cross-reactivity with second- and third-generation cephalosporins is negligible 2

Severe penicillin allergy (anaphylaxis/Type I hypersensitivity):

• Respiratory fluoroquinolones: levofloxacin 500 mg once daily or moxifloxacin 400 mg once daily for 10 days 2, 5, 4
• Doxycycline 100 mg once daily for 10 days (acceptable alternative but suboptimal, with 77-81% predicted efficacy vs. 90-92% for first-line agents) 2, 6

Never use azithromycin as first-line therapy due to resistance rates exceeding 20-25% for both S. pneumoniae and H. influenzae. 2, 3

Treatment Monitoring and Switching Antibiotics

Reassess at 3-5 days: If no improvement, switch to high-dose amoxicillin-clavulanate (2 g twice daily) or respiratory fluoroquinolone. 1, 2, 3

Reassess at 7 days: If symptoms persist or worsen, reconfirm diagnosis and consider complications or alternative diagnoses. 2, 3

Most patients show noticeable improvement within 3-5 days, with complete resolution by 10-14 days. 2, 3

Essential Adjunctive Therapies

Intranasal corticosteroids (mometasone, fluticasone, or budesonide twice daily) should be added to antibiotic therapy in all patients to reduce mucosal inflammation and improve symptom resolution. 1, 2, 3

Additional supportive measures:

• Saline nasal irrigation for symptomatic relief 1, 2, 3
• Analgesics (acetaminophen or ibuprofen) for pain and fever 1, 2, 3
• Adequate hydration 2

Do not use oral decongestants or antihistamines as adjunctive treatment—they are not recommended. 1

When to Refer to a Specialist

Refer to an otolaryngologist, infectious disease specialist, or allergist if:

• No improvement after 7 days of appropriate second-line antibiotic therapy 1, 2
• Worsening symptoms at any time 1, 2
• Suspected complications (orbital cellulitis, meningitis, brain abscess) 1, 2
• Recurrent sinusitis (≥3 episodes per year) 1, 2

---

Community-Acquired Pneumonia (Chest Bacterial Infection)

For adults with community-acquired pneumonia, the first-line antibiotic choice depends on severity and risk factors.

Outpatient Treatment (Mild-to-Moderate Disease)

Previously healthy, no recent antibiotic use:

• Amoxicillin 1 g three times daily 5
• Alternative: Doxycycline 100 mg twice daily 5

Comorbidities (COPD, diabetes, heart/liver/renal disease) or recent antibiotic use:

• Respiratory fluoroquinolone: levofloxacin 750 mg once daily for 5 days OR 500 mg once daily for 7-14 days 5, 4
• Alternative: Amoxicillin-clavulanate 2 g twice daily PLUS macrolide (if macrolide resistance not a concern) 5

Inpatient Treatment (Moderate-to-Severe Disease)

• Respiratory fluoroquinolone: levofloxacin 750 mg IV/PO once daily 5
• Alternative: Beta-lactam (ceftriaxone, ampicillin-sulbactam) PLUS macrolide 5

Levofloxacin achieves 90-92% predicted clinical efficacy against major respiratory pathogens, including multi-drug resistant Streptococcus pneumoniae (MDRSP). 5, 4

Coverage for Atypical Pathogens

Levofloxacin provides excellent coverage for atypical pathogens:

• Chlamydophila pneumoniae: 96% clinical success 5
• Mycoplasma pneumoniae: 96% clinical success 5
• Legionella pneumophila: 70% clinical success 5

Critical Pitfall to Avoid

Reserve fluoroquinolones appropriately. Do not use fluoroquinolones as routine first-line therapy in patients without documented beta-lactam allergies or risk factors, as this promotes antimicrobial resistance. 2, 3, 4